<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aust Prescr</journal-id><journal-id journal-id-type="iso-abbrev">Aust Prescr</journal-id><journal-id journal-id-type="publisher-id">AP</journal-id><journal-title-group><journal-title>Australian Prescriber</journal-title></journal-title-group><issn pub-type="ppub">0312-8008</issn><issn pub-type="epub">1839-3942</issn><publisher><publisher-name>NPS MedicineWise</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31937991</article-id><article-id pub-id-type="pmc">6954868</article-id><article-id pub-id-type="publisher-id">austprescr-42-204</article-id><article-id pub-id-type="doi">10.18773/austprescr.2019.073</article-id><article-categories><subj-group subj-group-type="heading"><subject>Top 10 Drugs</subject></subj-group></article-categories><title-group><article-title>Top 10 drugs 2018&#x02013;19</article-title></title-group><pub-date pub-type="epub"><day>02</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2019</year></pub-date><volume>42</volume><issue>6</issue><fpage>204</fpage><lpage>204</lpage><permissions><copyright-statement>(c) NPS MedicineWise 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>NPS MedicineWise</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license></permissions></article-meta></front><body><p>Tables <ext-link ext-link-type="uri" xlink:href="T1">1</ext-link>, <ext-link ext-link-type="uri" xlink:href="T2">2</ext-link> and <ext-link ext-link-type="uri" xlink:href="T3">3</ext-link> show the top 10 drugs for the year July 2018 &#x02013; June 2019. The figures are based on PBS and RPBS prescriptions from the date of supply. The figures include prescriptions under the co-payment (non-subsidised).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Top 10 PBS/RPBS drugs by DDD/1000 population/day</title></caption><table frame="hsides" rules="groups"><col width="49.98%" span="1"/><col width="50.02%" span="1"/><thead><tr><th valign="top" align="left" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">Drug</th><th valign="top" align="right" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">DDD/1000 pop/day*</th></tr></thead><tbody><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">1. atorvastatin</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">71 .35</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2. rosuvastatin</td><td valign="top" align="right" rowspan="1" colspan="1">57.44</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">3. perindopril</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">51 .67</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4. amlodipine</td><td valign="top" align="right" rowspan="1" colspan="1">47.95</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">5. candesartan</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">32.90</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6. irbesartan</td><td valign="top" align="right" rowspan="1" colspan="1">31.48</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">7. telmisartan</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">31.26</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">8. esomeprazole</td><td valign="top" align="right" rowspan="1" colspan="1">27.62</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">9. ramipril</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">26.97</td></tr><tr><td valign="top" align="left" style="border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">10. metformin</td><td valign="top" align="right" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">25.1 4</td></tr></tbody></table><table-wrap-foot><p>DDD defined daily dose</p><p>PBS Pharmaceutical Benefits Scheme</p><p>RPBS Repatriation Pharmaceutical Benefits Scheme</p><p>* DDD/1000 population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people in every thousand Australians are taking the standard dose of a drug every day. DDD includes use in combination products. The calculation is based on ABS 3101.0 &#x02013; Australian Demographic Statistics for December 2018.</p></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Top 10 PBS/RPBS drugs by prescription counts</title></caption><table frame="hsides" rules="groups"><col width="49.98%" span="1"/><col width="50.02%" span="1"/><thead><tr><th valign="top" align="left" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">Drug</th><th valign="top" align="right" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">Prescriptions</th></tr></thead><tbody><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">1. rosuvastatin</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">12,026,655</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2. atorvastatin</td><td valign="top" align="right" rowspan="1" colspan="1">10,967,105</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">3. esomeprazole</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">9,278,125</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4. pantoprazole</td><td valign="top" align="right" rowspan="1" colspan="1">7,375,606</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">5. perindopril</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">6,551 ,5 7 1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6. cefalexin</td><td valign="top" align="right" rowspan="1" colspan="1">5,643,287</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">7. amoxicillin</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">5,254,8 1 1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">8. metformin</td><td valign="top" align="right" rowspan="1" colspan="1">5,01 7,700</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">9. amoxicillin + clavulanic acid</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">4,706,645</td></tr><tr><td valign="top" align="left" style="border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">10. escitalopram</td><td valign="top" align="right" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">4,533,725</td></tr></tbody></table></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Top 10 PBS/RPBS drugs by cost to government (does not include rebates)</title></caption><table frame="hsides" rules="groups"><col width="25.01%" span="1"/><col width="24.99%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><thead><tr><th valign="top" align="left" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">Drug</th><th valign="top" align="right" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">Cost to government</th><th valign="top" align="right" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">DDD/1000 pop/day*</th><th valign="top" align="right" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">Prescriptions</th></tr></thead><tbody><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">1. sofosbuvir + velpatasvir&#x02020;</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">$391,007,833</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">&#x02021;</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">25,447</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2. aflibercept*</td><td valign="top" align="right" rowspan="1" colspan="1">$358,636,7 2 1</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02021;</td><td valign="top" align="right" rowspan="1" colspan="1">289,522</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">3. adalimumab</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">$3 17,436,1 7 5</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">0.74</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">246,220</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4. nivolumab*</td><td valign="top" align="right" rowspan="1" colspan="1">$267,738,344</td><td valign="top" align="right" rowspan="1" colspan="1">&#x02021;</td><td valign="top" align="right" rowspan="1" colspan="1">53,861</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">5. pembrolizumab*</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">$220,469,394</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">&#x02021;</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">25,676</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6. denosumab</td><td valign="top" align="right" rowspan="1" colspan="1">$218,970,1 1 8</td><td valign="top" align="right" rowspan="1" colspan="1">16.80</td><td valign="top" align="right" rowspan="1" colspan="1">786,535</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">7. ranibizumab*</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">$207,163,441</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">&#x02021;</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">180,7 2 1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">8. ustekinumab</td><td valign="top" align="right" rowspan="1" colspan="1">$178,790,589</td><td valign="top" align="right" rowspan="1" colspan="1">0.44</td><td valign="top" align="right" rowspan="1" colspan="1">25,7 3 1</td></tr><tr><td valign="top" align="left" style="background-color:rgb(242,242,242)" scope="row" rowspan="1" colspan="1">9. glecaprevir + pibrentasvir&#x02020;</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">$173,610,672</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">&#x02021;</td><td valign="top" align="right" style="background-color:rgb(242,242,242)" rowspan="1" colspan="1">9,207</td></tr><tr><td valign="top" align="left" style="border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">10. apixaban</td><td valign="top" align="right" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">$170,049,35 1</td><td valign="top" align="right" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">5.55</td><td valign="top" align="right" style="border-bottom: solid 0.50pt" rowspan="1" colspan="1">2,088,604</td></tr></tbody></table><table-wrap-foot><p>&#x02020; DDDs for combination products are accounted for in constituent drugs</p><p>&#x02021; The World Health Organization has not allocated a DDD for this drug</p><p>Source: Department of Health, December 2019. &#x000a9;Commonwealth of Australia</p></table-wrap-foot></table-wrap></body></article>